Weekly Policy Update: CBSA Submits Comment Letter to Senate Finance Committee’s Health Task Force Urging Repeal of the Medical Device Excise Tax

Friday, June 14, 2019


CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals

Thursday, June 13, 2019

WOBURN, Mass. (Jun. 12, 2019) – CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals.

Weekly Policy Update: CBSA Attends the 2019 BIO International Convention

Monday, June 10, 2019

Last week CBSA President and CEO Jennifer Jones Paton and Vice President Emily Roberts attended the 2019 BIO International Convention in Philadelphia. The event brings together over 16,000 attendees from around the world for educational sessions, networking events, and partnering meetings. For the CBSA team, it’s a great opportunity to connect with industry partners, biotechnology companies, and other state associations to discuss collaboration opportunities and share best practices.  

Colorado BioScience Association Celebrates State’s Collaborative Nature

Monday, June 03, 2019

New Magazine Offers In-Depth Financing Data and Insights on Medical Device and Drug Approvals 
Continue Reading

Seven Researchers Named Boettcher Investigators

Tuesday, May 28, 2019

Newest Class Marks 10th Group Selected Under Webb-Waring Program 
Continue Reading

Improving the Reimbursement Landscape for Medical Technology Innovators

Friday, May 24, 2019

CBSA continues to work with Congress and federal policymakers to improve the reimbursement landscape for medical technology innovators. Even when groundbreaking and innovative technologies meet FDA’s rigorous standards, device manufacturers face other significant hurdles in navigating the coverage and reimbursement process. In fact, many technology manufacturers do not pursue national coverage decisions because they are too time consuming and cumbersome.  

27 Companies Share 6.1 Million Dollars in 2019 Advanced Industries Accelerator Grants

Wednesday, May 22, 2019

Colorado BioScience Association congratulates the 27 companies recently recognized as valuable investments for the entire state by the Office of Economic Development and International Trade’s (OEDIT) Advanced Industries (AI) Grants Program. The growth and success of Colorado’s life science ecosystem would not be as robust as it is today without this valuable assistance from the state’s Advanced Industries (AI) Accelerator Grant Program. Special congratulations to the bioscience companies who were awarded funding this round:  

CMS Rolls Back Harmful Proposals in Medicare Part D

Monday, May 20, 2019


ArcherDX Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio

Wednesday, May 15, 2019

BOULDER, Colo., May, 15, 2019 /PRNEWSWIRE/-- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced the closing of an up to $60 million Series B financing round led by Perceptive Advisors. The investor syndicate also includes existing investors PBM Capital, Boulder Ventures, Longwood Fund and Peierls Foundation.  

Weekly Policy Update: CMS Proposed Rule is a Step Forward for the Coverage of Breakthrough Technologies

Monday, May 13, 2019

In late April, the Centers for Medicare and Medicaid Services (CMS) publicly released its FY 2020 Inpatient Prospective Payment System (IPPS) Proposed Rule. The rule is a critical step forward for coverage and payment of medical devices, and makes it more likely that breakthrough products will be covered and adequately paid for by CMS.